Cell therapy that targets lung inflammation and tissue damage. COPD, asthma, pulmonary fibrosis, and long COVID.
Long-term lung conditions share one core problem. Ongoing inflammation and growing damage to lung tissue that standard medicine can slow but rarely reverse. COPD destroys alveoli, the tiny air sacs that handle oxygen exchange. Pulmonary fibrosis replaces healthy lung tissue with scar tissue. Over time, this lowers lung capacity. Asthma involves long-term airway inflammation that can reshape the airways. Long COVID has added a whole new type of lung damage in many patients who had severe or moderate COVID-19.
MSCs (mesenchymal stem cells) have shown anti-inflammatory and tissue-protecting effects in lung conditions in clinical research. When delivered through IV, MSCs travel mostly to the lungs. This is called the pulmonary first-pass effect. Once in lung tissue, they release anti-inflammatory cytokines (cell signals). They lower scar tissue signals. They protect existing alveolar cells from more damage. They also activate local lung repair cells. The result is not a cure. Often it is a real gain in lung capacity, less shortness of breath, better exercise tolerance, and slower disease progress.
Dr. Gutiérrez reviews each respiratory patient one at a time. He looks at lung function tests, CT scans, oxygen saturation patterns, and inflammation markers before he builds a plan. For long COVID patients, the review also looks at full-body inflammation, immune balance, and autonomic system effects. Long COVID lung symptoms are often part of a wider syndrome that needs full-body care.
Physician-reviewed protocols · Nuevo Vallarta, Mexico